Filariasis clinical trials
The registry lists 23 studies for Filariasis across more than 10 countries. 2 are recruiting or about to start. 8 of them are mainly about Filariasis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30. Counting its 2 narrower conditions too, such as Elephantiasis, Filarial: 80 studies, 9 open.
Get an email when these change. Save the Filariasis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Washington University School of Medicine (4) · Drugs for Neglected Diseases (4) · The Task Force for Global Health (3) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Swiss Tropical & Public Health Institute (1) · University of Washington (1) · Vanderbilt University Medical Center (1)
What is being tested here
Drugs under test in Filariasis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Albendazole | 1 | 2 | 2 |
| Emodepside | 0 | 0 | 3 |
| Doxycycline | 0 | 3 | 3 |
| Oxfendazole | 0 | 0 | 1 |
| Reslizumab | 0 | 0 | 1 |
| Praziquantel | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 202621-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia · Phase 3 · Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Who these studies take
Of the 1 Filariasis studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 23 studies, recruiting or not: 61% stop at 75 or younger and 57% at 65; 61% take children; 0% are for women only and 13% for men only; 57% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. search them.
- 21-day Double-blind Trial of Albendazole in Adults With Loa Loa MicrofilaremiaNot yet recruitingNCT06613997Phase 3
- A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected SubjectsRecruitingNCT06252961Phase 2/31 country
- Host Response to Infection and Treatment in Filarial DiseasesActive, not recruitingNCT000012301 country
- Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)CompletedNCT03014167Phase 33 countries
- Emodepside Phase II Trial for Treatment of OnchocerciasisActive, not recruitingNCT05180461Phase 22 countries
- PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole TabletsCompletedNCT04920292Phase 11 country
- Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for LiberiaCompletedNCT019054361 country
- Reslizumab to Prevent Post-treatment Eosinophilia in LoiasisCompletedNCT01111305Phase 21 country
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in MaliCompletedNCT02927496Phase 31 country
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in IndiaCompletedNCT02929121Phase 31 country
- Effect of Filarial Infection on Immune Responses in Latent TuberculosisCompletedNCT015478842 countries
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri LankaCompletedNCT02929134Phase 31 country
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and OnchocerciasisCompletedNCT019054231 country
- Safety, Tolerability and PK of Multiple-ascending Doses of EmodepsideCompletedNCT03383614Phase 11 country
- First in Man Clinical Trial of Emodepside (BAY 44-4400)CompletedNCT02661178Phase 11 country
- Relative Bioavailability Study of Emodepside IR-tablets and SolutionCompletedNCT03383523Phase 11 country
- Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With SchistosomiasisWithdrawnNCT02734186Phase 4
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)CompletedNCT020320431 country
- Medical Implications of Coinfection With Malaria and Filariasis ParasitesCompletedNCT004716661 country
- Immune Response Regulation in People Infected Concurrently With Malarial and Filarial ParasitesCompletedNCT003416661 country
- Exhaled NO Testing in FilariasisCompletedNCT016284971 country
- Research for Elim of FilariasisCompletedNCT001452231 country
- Research for Elimination of Lymphatic Filariasis (ICIDR)CompletedNCT004066271 country